Effects of idebenone (CV-2619) on metabolism of monoamines, especially serotonin, in the brain of normal rats and rats with cerebral ischemia.
スポンサーリンク
概要
- 論文の詳細を見る
The effects of 6-(10-hydroxydecyl)-2, 3-dimethoxy-5-methyl-1, 4-benzoquinone (idebenone, CV-2619) on the contents, turnover, release and uptake of monoamines, especially serotonin (5-HT), in various brain regions of Wistar rats were studied in vivo and in vitro. In normal rats, an intraperitoneal (i.p.) dose of 100 mg/kg of CV-2619 had no significant effect on the levels of norepinephrine (NE), dopamine (DA) and their metabolites, and 5-HT in the brain regions examined, but it increased the levels of 5-hydroxyl ndole-3-acetic acid (5-HIAA), the main metabolite of 5-HT, in many brain regions. In rats with cerebral ischemia, a low dose (10 mg/kg, i.p.) of CV-2619 normalized the decreased levels of 5-HIAA in the cerebral cortex, hippocampus, diencephalon and brain stem. A 5-HT biosynthesis inhibitor, DL-p-chlorophenylalanine (PCPA, 150 mg/kg, i.p.), decreased the levels of 5-HT in all brain regions to one-third of the control levels 24 hr after administration in normal rats. CV-2619 (10, 30 or 100 mg/kg, i.p.), administered 24 hr after the treatment with PCPA, accelerated the PCPA-induced 5-HT decreases in the hippocampus, diencephalon and brain stem in a dose-dependent manner. In vitro CV-2619, like p-chloroamphetamine (PCA), stimulated 5-HT release from slices of the hippocampus and diencephalon. CV-2619 slightly inhibited and PCA markedly inhibited 5-HT uptake into hippocampal slices. The mechanism of the 5-HT releasing action of CV-2619 in hippocampal slices seems to be mediated through endogenous calcium. These results suggest that CV-2619 has an enhancing effect on the turnover of 5-HT in the hippocampus, diencephalon and brain stem of rats.
- 公益社団法人 日本薬理学会の論文
著者
-
NARUMI SHIGEHIKO
Central Research Division, Takeda Chemical Industries, Ltd.
-
Nagawa Yuji
Central Research Division Takeda Chemical Industries Ltd.
-
Nagai Yasuo
Central Research Division Takeda Chemical Industries Ltd.
-
KAKIHANA Mitsuru
Central Research Division, Takeda Chemical Industries, Ltd.
-
YAMAZAKI Naoki
Central Research Division, Takeda Chemical Industries, Ltd.
-
NAGAOKA Akinobu
Central Research Division, Takeda Chemical Industries, Ltd.
関連論文
- MECHANISM OF ANTIPENTOBARBITAL ACTION OF THYROTROPIN-RELEASING HORMONE (TRH)
- BLOOD LEVEL AND BRAIN DISTRIBUTION OF THYROTROPIN-RELEASING HORMONE (TRH) DETERMINED BY RADIOIMMUNOASSAY AFTER INTRAVENOUS ADMINISTRATION IN RATS
- A TRH analog (DN-1417): Effects on local cerebral glucose utilization in conscious and pentobarbitalized rats determined by the autoradiographic 2-deoxy-(14C)glucose method.
- Increase in rat regional brain cyclic nucleotides by thyrotropin-releasing hormone (TRH) and its analog DN-1417.
- Effects of idebenone (CV-2619) on metabolism of monoamines, especially serotonin, in the brain of normal rats and rats with cerebral ischemia.
- Effects of TRH and an Analog, DN-1417 on the Activities of Single Neurons in the Nucleus Accumbens, Cerebral Cortex and Caudate-putamen of Rats
- Effects of idebenone (CV-2619) on endogenous monoamine release and cyclic AMP formation in diencephalon slices from rats.
- Pharmacologic characterization of a novel non-benzodiazepine selective anxiolytic, DN-2327.
- Beneficial effect of idebenone (CV-2619) on cerebral ischemia-induced amnesia in rats.
- A possible mechanism of action of thyrotropin-releasing hormone (TRH) and its analog DN-1417 on the release of dopamine from the nucleus accumbens and striatum in rats.
- In vivo electrochemical detection of 5-hydroxyindoles in the dorsal hippocampus of anesthetized rats treated with idebenone (CV-2619).